Looks like UBS does not expect Nestle (NESN) to enter the bidding for Cadbury (CBRY). UBS analyst Alan Erskine upgraded the company on the basis that Nestle could return a third of its stock market value in buybacks and dividends over the next four years were it to start a new 25 billion-Swiss franc ($37.3 [...]

I wrote about this back in February when the market was putting in its lows and everyone was wondering what their stock's price target was or how low it was going to go. Today, after a pretty big run up, people are still wondering what their stock's price target is, but now they're wondering how high it's going to go. Either way, it's important for everyone to know how to calculate their stock's price target. You can do this by using either technicals or fundamentals. Today, I'm going to focus on fundamentals. And we're going to use the P/E ratio to calculate it. Many people use P/E ratios to determine a company's perceived undervaluation or overvaluation. But you can also use the P/E ratio to determine a stock's upside and downside price targets as well. The[More...]

Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction (FSD). The Company ended 3Q08 with $17.5M in cash, compared to $22.8M at the end of 2Q08. As illustrated on the accompanying all-data stock price chart for[More...]

The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer, Schering-Plough and Bristol-Myers Squibb reaching lower lows, one has to wonder when the pain will end as these companies[More...]

Sciele Pharma (SCRX) - 7/15/08LARx (head lice product) NDADifferent mode of action versus current neurotoxic lice killersTheravance (THRX) - 7/21/08Telavancin NDAA good chance for a second approvable letter due to outstanding issues with trial conduct ...